Overview

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Korea Otsuka Pharmaceutical Co., Ltd.
Treatments:
Aripiprazole